On April 30, 2026, the U.S. Food and Drug Administration published a Federal Register notice proposing to exclude semaglutide, tirzepatide and liraglutide from the 503B bulks list. If finalized, the rule would prohibit outsourcing facilities from legally compounding these drugs from bulk drug substances.
The public comment period runs through June 29, 2026. The proposal represents a decisive regulatory action to consolidate the GLP-1 market under approved drug manufacturers.
Compounding of GLP-1 drugs became widespread during 2023-2024 when severe supply shortages left millions of patients unable to access FDA-approved versions. Under section 503B, outsourcing facilities were permitted to compound these drugs when they appeared on the FDA drug shortage list.
The supply landscape has shifted dramatically. The FDA removed tirzepatide from the shortage list in December 2024 and semaglutide in February 2025. With branded supply now meeting patient demand, the FDA determined there is no longer a clinical need for outsourced compounding.
The proposal has direct implications for the peptide API supply chain. Outsourcing facilities have been major purchasers of bulk semaglutide, tirzepatide and liraglutide API. The 503B compounding market for GLP-1 drugs was estimated at several billion dollars annually. API suppliers serving this segment face potential volume reductions of 30 to 50 percent as compounders exit the market.
Approved drug manufacturers operate under stricter cGMP requirements than outsourcing facilities. API suppliers must maintain compliance with more rigorous quality standards and documentation requirements. The shift may favor larger, more established API manufacturers with proven regulatory track records.
Peptide API manufacturing is a specialized field requiring expertise in solid-phase peptide synthesis, purification and quality control. The GLP-1 class presents unique challenges: semaglutide is a 31-amino acid peptide with fatty acid side chain modification, tirzepatide is a dual GIP/GLP-1 receptor agonist with 39 amino acids, and liraglutide is a 31-amino acid GLP-1 analog with palmitic acid modification.
API suppliers with significant 503B compounding exposure should diversify their customer base. Quality systems should be aligned with approved drug manufacturer requirements. Long-term supply agreements with branded drug manufacturers become increasingly valuable.
Novo Nordisk and Eli Lilly have invested billions in manufacturing expansion, creating demand for raw materials, intermediates and fill-finish services. Emerging oral GLP-1 therapies require different manufacturing capabilities. The global GLP-1 drug market is projected to reach 130 to 150 billion dollars annually by 2030.
The proposed rule represents a broader trend toward regulatory consolidation in the GLP-1 market. For API and peptide suppliers, the strategic imperative is clear: align with the approved drug supply chain, invest in quality systems meeting the most rigorous regulatory standards, and position for the long-term growth of the GLP-1 therapeutic class.
